Robert Stuver
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Robert Stuver has a total of 517 co-authors. Here are the top co-authors by number of shared publications:
Steven M. Horwitz
Lymphoma Service, Division of Hematological Malignancies, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY
18 shared publicationsAlison J. Moskowitz
Memorial Sloan Kettering Cancer Center, New York
12 shared publications- Ahmet Dogan
Memorial Sloan Kettering Cancer Center, New York, NY
7 shared publications - Gilles Salles
Memorial Sloan Kettering Cancer Center, New York, NY
7 shared publications Nivetha Ganesan
Memorial Sloan Kettering Cancer Center, New York
7 shared publicationsPaola Ghione
Memorial Sloan Kettering Cancer Center, New York
7 shared publications
Latest Publications
- Open Access
- 2 November 2026
- Published by American Society of Hematology in Blood Advances
- Vol. 10 (21) , 7393-7405
Zanubrutinib, obinutuzumab, and venetoclax in CLL: long-term follow up, MRD kinetics, retreatment, T-cell profiling, and PKs
Triplet regimens induce high rates of undetectable measurable residual disease (MRD) at ≤10−4 (uMRD4) and appear to prolong progression-free survival (PFS) in treatment-naïve (TN) chronic lymphocytic leukemia (CLL), but the optimal treatment duration to minimize the risk of infections is unknown. In this phase 2 trial, we evaluated zanubrutinib, obinutuzumab, and venetoclax (BOVen) in TN CLL. Our MRD-driven study was designed to optimize treatment duration, balancing efficacy against toxicities associated with extended treatment exposure, and to evaluate zanubrutinib with venetoclax (Z+V) retreatment. With a median observation of 69 months and median treatment duration of 10 cycles, 96% achieved blood uMRD4, and 92% achieved uMRD4 in both blood and bone marrow (primary end point). BOVen was well-tolerated, with low rates of grade 3-4 neutropenia (25%) and infections (9.6%; no grade 5). Median MRD4-free survival was 34.1 months (95% confidence interval [CI], 23.1-50.5), and the 48-month PFS was 79.7% (95% CI, 68.6-92.5). ΔMRD400 (≥400-fold reduction in blood MRD [immunosequencing] at 4 months) identified patients with earlier bone marrow uMRD4 (6 vs 12 months, P< .001) and longer MRD4-free survival (50.5 vs 18.1 months, P< .001), despite shorter treatment duration (8 vs 13 months, P< .001). This manuscript also reports safety/efficacy of Z+V retreatment and pharmacokinetic and T-cell profiling studies. In summary, BOVen was well-tolerated and resulted in frequent uMRD4 and durable remissions in TN CLL with a short treatment duration (median, 10 months). ΔMRD400 is undergoing evaluation as a predictive biomarker to guide treatment duration in two prospective trials of venetoclax- and sonrotoclax-based triplets in TN CLL. This trial was registered at www.clinicaltrials.gov (#NCT03824483).
- 2 November 2026
- Published by American Society of Hematology in Blood Advances
- Vol. 10 (21) , 7393-7405
Open AccessZanubrutinib, obinutuzumab, and venetoclax in CLL: long-term follow up, MRD kinetics, retreatment, T-cell profiling, and PKs
Triplet regimens induce high rates of undetectable measurable residual disease (MRD) at ≤10−4 (uMRD4) and appear to prolong progression-free survival (PFS) in treatment-naïve (TN) chronic lymphocytic leukemia (CLL), but the optimal treatment duration to minimize the risk of infections is unknown. In this phase 2 trial, we evaluated zanubrutinib, obinutuzumab, and venetoclax (BOVen) in TN CLL. Our MRD-driven study was designed to optimize treatment duration, balancing efficacy against toxicities associated with extended treatment exposure, and to evaluate zanubrutinib with venetoclax (Z+V) retreatment. With a median observation of 69 months and median treatment duration of 10 cycles, 96% achieved blood uMRD4, and 92% achieved uMRD4 in both blood and bone marrow (primary end point). BOVen was well-tolerated, with low rates of grade 3-4 neutropenia (25%) and infections (9.6%; no grade 5). Median MRD4-free survival was 34.1 months (95% confidence interval [CI], 23.1-50.5), and the 48-month PFS was 79.7% (95% CI, 68.6-92.5). ΔMRD400 (≥400-fold reduction in blood MRD [immunosequencing] at 4 months) identified patients with earlier bone marrow uMRD4 (6 vs 12 months, P< .001) and longer MRD4-free survival (50.5 vs 18.1 months, P< .001), despite shorter treatment duration (8 vs 13 months, P< .001). This manuscript also reports safety/efficacy of Z+V retreatment and pharmacokinetic and T-cell profiling studies. In summary, BOVen was well-tolerated and resulted in frequent uMRD4 and durable remissions in TN CLL with a short treatment duration (median, 10 months). ΔMRD400 is undergoing evaluation as a predictive biomarker to guide treatment duration in two prospective trials of venetoclax- and sonrotoclax-based triplets in TN CLL. This trial was registered at www.clinicaltrials.gov (#NCT03824483).
- 25 September 2026
- Published by American Society of Hematology in Blood Advances
- Vol. 10 (19) , 6538-6550
Clinical outcomes, patterns of relapse, and molecular landscape of advanced stage high-grade B-cell lymphoma
High-grade B-cell lymphoma (HGBCL) is an aggressive clinical entity characterized by poor overall survival and high rates of central nervous system (CNS) relapse. HGBCL includes cases harboring MYC rearrangement with concurrent BCL2 and/or BCL6 rearrangements (BCL2-R and/or BCL6-R). However, the prognostic implications of different rearrangements combinations (MYC/BCL2, MYC/BCL6, or MYC/BCL2/BCL6) remains an open question, with differing reports in the literature, and our knowledge of the clinical characteristics, response to treatment, and patterns of relapse remains incomplete. We identified clinical data from 124 subjects with advanced-stage HGBCL treated at Memorial Sloan Kettering Cancer Center (69 MYC/BCL2-R, 34 MYC/BCL2/BCL6-R [“triple hit”], and 21 MYC/BCL6-R). Thirty-six cases were subjected to targeted next-generation sequencing with MSK-IMPACT HEME. We confirm the poor prognosis of HGBCL, with low complete response rates (44%), poor overall survival (59.8% at 2 years), and high rates of CNS relapse (10.1%). Intensive regimens such as dose-adjusted R-EPOCH were associated with improved overall survival compared to R-CHOP–based regimens. Unexpectedly, patients with MYC/BCL6-R disease had increased incidence of CNS relapse and rapid progression to death after relapse; we observed differing cell of origin in these cases compared with BCL2-R disease. In addition, counter to previous reports in diffuse large B-cell lymphoma (DLBCL), HGBCL transformed from low-grade lymphoma was associated with improved survival in our cohort. Mutational profiling of HGBCL cases demonstrated enrichment for mutations associated with DLBCL, particularly germinal center–derived cases, as well as a high proportion of MYC mutations. Our results support the poor prognosis of HGBCL and the recent separation of MYC/BCL6 disease as a distinct clinical entity.
- 25 September 2026
- Published by American Society of Hematology in Blood Advances
- Vol. 10 (19) , 6538-6550
Clinical outcomes, patterns of relapse, and molecular landscape of advanced stage high-grade B-cell lymphoma
High-grade B-cell lymphoma (HGBCL) is an aggressive clinical entity characterized by poor overall survival and high rates of central nervous system (CNS) relapse. HGBCL includes cases harboring MYC rearrangement with concurrent BCL2 and/or BCL6 rearrangements (BCL2-R and/or BCL6-R). However, the prognostic implications of different rearrangements combinations (MYC/BCL2, MYC/BCL6, or MYC/BCL2/BCL6) remains an open question, with differing reports in the literature, and our knowledge of the clinical characteristics, response to treatment, and patterns of relapse remains incomplete. We identified clinical data from 124 subjects with advanced-stage HGBCL treated at Memorial Sloan Kettering Cancer Center (69 MYC/BCL2-R, 34 MYC/BCL2/BCL6-R [“triple hit”], and 21 MYC/BCL6-R). Thirty-six cases were subjected to targeted next-generation sequencing with MSK-IMPACT HEME. We confirm the poor prognosis of HGBCL, with low complete response rates (44%), poor overall survival (59.8% at 2 years), and high rates of CNS relapse (10.1%). Intensive regimens such as dose-adjusted R-EPOCH were associated with improved overall survival compared to R-CHOP–based regimens. Unexpectedly, patients with MYC/BCL6-R disease had increased incidence of CNS relapse and rapid progression to death after relapse; we observed differing cell of origin in these cases compared with BCL2-R disease. In addition, counter to previous reports in diffuse large B-cell lymphoma (DLBCL), HGBCL transformed from low-grade lymphoma was associated with improved survival in our cohort. Mutational profiling of HGBCL cases demonstrated enrichment for mutations associated with DLBCL, particularly germinal center–derived cases, as well as a high proportion of MYC mutations. Our results support the poor prognosis of HGBCL and the recent separation of MYC/BCL6 disease as a distinct clinical entity.
- Open Access
- 11 June 2026
- Published by Ferrata Storti Foundation (Haematologica) in Haematologica
Outcomes in early stage peripheral T-cell lymphoma by stage, histology, and treatment patterns
Peripheral T-cell lymphomas are rare, generally aggressive lymphomas. Early stage disease represents a minority, and current treatment guidelines generally do not distinguish by stage or do so based on limited evidence. In order to understand practices and outcomes in this setting, we evaluated a multicenter cohort of patients with early stage nodal T-cell lymphomas (peripheral Tcell lymphoma, not otherwise specified [PTLC-NOS], nodal T-follicular helper cell lymphoma [TFHL], and anaplastic lymphoma kinase-negative anaplastic large cell lymphoma [ALK-negative ALCL]) from 2001 to 2022. We evaluated differences in outcomes by stage, histology, and treatment strategy, including consolidation after chemotherapy, which often includes radiation therapy (RT) and sometimes includes autologous stem cell transplant (ASCT). In total, we identified 132 patients. All patients received chemotherapy, 78 (59%) received chemotherapy plus RT, and 18 (14%) received ASCT. For the entire cohort, five-year progression-free (PFS) and overall survival (OS) was 56% and 68%. Outcomes were particularly encouraging in stage I disease, with five-year PFS and OS of 66% and 79%. Among patients with stage I disease responding to chemotherapy, patients treated with chemoradiation had especially favorable outcomes (five-year PFS: 70%, OS: 86%). Among patients with stage II disease responding to chemotherapy, outcomes were inferior to those with stage I disease and were similar regardless of treatment strategy. These findings show improved outcomes in early stage nodal T-cell lymphomas compared to historical data for allcomers. In addition, favorable outcomes in stage I disease treated with chemoradiation support such strategy as an excellent treatment option in this setting.
- 11 June 2026
- Published by Ferrata Storti Foundation (Haematologica) in Haematologica
Open AccessOutcomes in early stage peripheral T-cell lymphoma by stage, histology, and treatment patterns
Peripheral T-cell lymphomas are rare, generally aggressive lymphomas. Early stage disease represents a minority, and current treatment guidelines generally do not distinguish by stage or do so based on limited evidence. In order to understand practices and outcomes in this setting, we evaluated a multicenter cohort of patients with early stage nodal T-cell lymphomas (peripheral Tcell lymphoma, not otherwise specified [PTLC-NOS], nodal T-follicular helper cell lymphoma [TFHL], and anaplastic lymphoma kinase-negative anaplastic large cell lymphoma [ALK-negative ALCL]) from 2001 to 2022. We evaluated differences in outcomes by stage, histology, and treatment strategy, including consolidation after chemotherapy, which often includes radiation therapy (RT) and sometimes includes autologous stem cell transplant (ASCT). In total, we identified 132 patients. All patients received chemotherapy, 78 (59%) received chemotherapy plus RT, and 18 (14%) received ASCT. For the entire cohort, five-year progression-free (PFS) and overall survival (OS) was 56% and 68%. Outcomes were particularly encouraging in stage I disease, with five-year PFS and OS of 66% and 79%. Among patients with stage I disease responding to chemotherapy, patients treated with chemoradiation had especially favorable outcomes (five-year PFS: 70%, OS: 86%). Among patients with stage II disease responding to chemotherapy, outcomes were inferior to those with stage I disease and were similar regardless of treatment strategy. These findings show improved outcomes in early stage nodal T-cell lymphomas compared to historical data for allcomers. In addition, favorable outcomes in stage I disease treated with chemoradiation support such strategy as an excellent treatment option in this setting.
- Open Access
- 27 May 2026
- Published by American Society of Hematology in Blood Advances
- Vol. 10 (11) , 3833-3844
Impact of novel therapies on the efficacy of posttransplantation brentuximab vedotin maintenance in Hodgkin lymphoma
Use of brentuximab vedotin (BV) and PD-1 monoclonal antibodies (mAbs) before autologous stem cell transplantation (ASCT) could impact the benefit of post-ASCT BV maintenance in relapsed/refractory (R/R) classic Hodgkin lymphoma (cHL). We identified 1091 patients with R/R cHL who underwent ASCT between 2010-2022. In total, 244 (22%) received a PD-1 mAb and 443 (41%) received BV before ASCT, while 305 (28%) received BV maintenance. We performed 1:1 propensity score matching to assess the efficacy of BV maintenance in different patient subgroups. Among 608 matched patients, the 3-year progression-free survival (PFS) and overall survival were 73% (95% confidence interval [CI], 70-78) and 95% (95%CI, 93-97), respectively. BV maintenance was associated with improved PFS for patients with no exposure to novel agents, especially those with 2+ modified AETHERA risk factors (0-1 factors: hazard ratio (HR), 0.51; 95%CI, 0.24-1.09; P =.083; 2+ factors: HR, 0.40; 95%CI, 0.25-0.65; P< .001). In contrast, BV maintenance was not associated with a significant PFS benefit for any patient subgroup who received novel agents before ASCT (BV-treated, 0-1: HR, 1.43; 95%CI, 0.53-3.81; P =.48; 2+: HR, 0.79; 95%CI, 0.34-1.82; P =.58; PD-1-treated, 0-1 [P>.99], 2+: HR, 0.25; 95%CI, 0.03-2.14; P =.21). In particular, we observed excellent outcomes for patients undergoing ASCT in a complete response after one line of PD-1-based salvage treatment with no significant benefit for BV maintenance observed (2-year PFS 100% vs 95%; P>.99). The benefit of BV maintenance appears to be attenuated for patients receiving novel agents with salvage therapy. Omission of BV maintenance should be considered for patients anticipated to have excellent outcomes.
- 27 May 2026
- Published by American Society of Hematology in Blood Advances
- Vol. 10 (11) , 3833-3844
Open AccessImpact of novel therapies on the efficacy of posttransplantation brentuximab vedotin maintenance in Hodgkin lymphoma
Use of brentuximab vedotin (BV) and PD-1 monoclonal antibodies (mAbs) before autologous stem cell transplantation (ASCT) could impact the benefit of post-ASCT BV maintenance in relapsed/refractory (R/R) classic Hodgkin lymphoma (cHL). We identified 1091 patients with R/R cHL who underwent ASCT between 2010-2022. In total, 244 (22%) received a PD-1 mAb and 443 (41%) received BV before ASCT, while 305 (28%) received BV maintenance. We performed 1:1 propensity score matching to assess the efficacy of BV maintenance in different patient subgroups. Among 608 matched patients, the 3-year progression-free survival (PFS) and overall survival were 73% (95% confidence interval [CI], 70-78) and 95% (95%CI, 93-97), respectively. BV maintenance was associated with improved PFS for patients with no exposure to novel agents, especially those with 2+ modified AETHERA risk factors (0-1 factors: hazard ratio (HR), 0.51; 95%CI, 0.24-1.09; P =.083; 2+ factors: HR, 0.40; 95%CI, 0.25-0.65; P< .001). In contrast, BV maintenance was not associated with a significant PFS benefit for any patient subgroup who received novel agents before ASCT (BV-treated, 0-1: HR, 1.43; 95%CI, 0.53-3.81; P =.48; 2+: HR, 0.79; 95%CI, 0.34-1.82; P =.58; PD-1-treated, 0-1 [P>.99], 2+: HR, 0.25; 95%CI, 0.03-2.14; P =.21). In particular, we observed excellent outcomes for patients undergoing ASCT in a complete response after one line of PD-1-based salvage treatment with no significant benefit for BV maintenance observed (2-year PFS 100% vs 95%; P>.99). The benefit of BV maintenance appears to be attenuated for patients receiving novel agents with salvage therapy. Omission of BV maintenance should be considered for patients anticipated to have excellent outcomes.
- 14 March 2026
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 67 (6) , 1440-1446
Clinical outcomes of mature T- and NK-cell lymphomas in hepatitis B virus positive individuals: results from the PETAL Global Consortium
Approximately 10% of all cancers worldwide have been attributed to an underlying viral infection [1]. Regarding lymphoid malignancies, viral infections have been linked to several of these cancers ...
- 14 March 2026
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 67 (6) , 1440-1446
Clinical outcomes of mature T- and NK-cell lymphomas in hepatitis B virus positive individuals: results from the PETAL Global Consortium
Approximately 10% of all cancers worldwide have been attributed to an underlying viral infection [1]. Regarding lymphoid malignancies, viral infections have been linked to several of these cancers ...
- Top Cited Papers
- 5 March 2026
- Published by American Society of Hematology in Blood
- Vol. 147 (10) , 1125-1134
PD-1–based combinations before autologous transplant are associated with improved outcomes in classical Hodgkin lymphoma
Combination therapy incorporating programmed cell death protein 1 (PD-1) blockade results in unprecedented response rates in both frontline and relapsed/refractory (R/R) classical Hodgkin lymphoma (cHL). Previous retrospective studies have suggested benefit for PD-1 blockade before autologous stem cell transplant (ASCT) but included few patients receiving PD-1 blockade with cytotoxic chemotherapy. To explore the impact of anti–PD-1 based salvage on outcomes for patients with R/R cHL, we retrospectively reviewed 1280 patients with R/R cHL who underwent ASCT from 2010 to 2022 at 6 transplant centers, none of whom received PD-1 blockade as part of frontline therapy. Overall, 25% received a PD-1 inhibitor at any point before ASCT (10% in conjunction with chemotherapy), 28% received salvage brentuximab vedotin (BV) without PD-1 blockade, and the rest received salvage chemotherapy alone. Patients who received PD-1 inhibitors at any point before ASCT had a significantly higher 2-year progression-free survival than those who received BV without PD-1 inhibitors or patients receiving chemotherapy alone (88.2%, 70.2%, and 67.4%, respectively; P< .0001). When restricted to patients in complete response before ASCT, the benefit of PD-1 blockade remained significant. PD-1 blockade before ASCT is independently associated with superior post-ASCT outcomes and patients proceeding to ASCT should be treated with PD-1–based salvage.
- 5 March 2026
- Published by American Society of Hematology in Blood
- Vol. 147 (10) , 1125-1134
Top Cited PapersPD-1–based combinations before autologous transplant are associated with improved outcomes in classical Hodgkin lymphoma
Combination therapy incorporating programmed cell death protein 1 (PD-1) blockade results in unprecedented response rates in both frontline and relapsed/refractory (R/R) classical Hodgkin lymphoma (cHL). Previous retrospective studies have suggested benefit for PD-1 blockade before autologous stem cell transplant (ASCT) but included few patients receiving PD-1 blockade with cytotoxic chemotherapy. To explore the impact of anti–PD-1 based salvage on outcomes for patients with R/R cHL, we retrospectively reviewed 1280 patients with R/R cHL who underwent ASCT from 2010 to 2022 at 6 transplant centers, none of whom received PD-1 blockade as part of frontline therapy. Overall, 25% received a PD-1 inhibitor at any point before ASCT (10% in conjunction with chemotherapy), 28% received salvage brentuximab vedotin (BV) without PD-1 blockade, and the rest received salvage chemotherapy alone. Patients who received PD-1 inhibitors at any point before ASCT had a significantly higher 2-year progression-free survival than those who received BV without PD-1 inhibitors or patients receiving chemotherapy alone (88.2%, 70.2%, and 67.4%, respectively; P< .0001). When restricted to patients in complete response before ASCT, the benefit of PD-1 blockade remained significant. PD-1 blockade before ASCT is independently associated with superior post-ASCT outcomes and patients proceeding to ASCT should be treated with PD-1–based salvage.
- Top Cited Papers
- 26 February 2026
- Published by American Society of Hematology in Blood
- Vol. 147 (9) , 960-972
CXCL9 as a novel prognostic marker to identify high-risk adults with hemophagocytic lymphohistiocytosis
Hemophagocytic lymphohistiocytosis (HLH) is an interferon gamma–driven hyperinflammatory syndrome with high morbidity and mortality. Identifying reliable prognostic biomarkers is challenging due to various predisposing conditions and triggers. C-X-C-motif ligand 9 (CXCL9) is a clinically validated biomarker and surrogate marker of interferon gamma–mediated inflammation. We aimed to identify the role of CXCL9 in predicting severe disease and death in adults with HLH using a multicenter retrospective cohort of consecutively hospitalized patients who underwent a clinical evaluation for HLH that included CXCL9 testing. Patients were classified as HLH if they met HLH-2004 and/or HScore criteria. Conditional inference decision trees and Cox regression models were used to identify which clinical variables associated with acute mortality in patients with HLH. Overall, 171 patients were reviewed, and 126 patients met HLH criteria. The median age was 55 years (interquartile range, 40-66), with 62% male and 51% White. CXCL9 was markedly elevated in patients with HLH. Unbiased decision tree modeling, incorporating all clinical laboratory values, identified only CXCL9 of >16 100 pg/mL as the optimal predictor of inpatient mortality. Cox regression models demonstrated that CXCL9 of >16 100 pg/mL was significantly associated with 90-day mortality when controlling for important covariates. This shorter time to death in the elevated CXCL9 subgroup remained significant even after subdividing patients into those with malignancy (n = 53) and nonmalignancy HLH (n = 73). Continuous increases in CXCL9 within the cohort strongly associated with greater mortality. CXCL9 is a novel clinical marker that identifies high-risk HLH independent of underlying disease and could be used to select patients for early and aggressive targeted immunomodulatory therapy.
- 26 February 2026
- Published by American Society of Hematology in Blood
- Vol. 147 (9) , 960-972
Top Cited PapersCXCL9 as a novel prognostic marker to identify high-risk adults with hemophagocytic lymphohistiocytosis
Hemophagocytic lymphohistiocytosis (HLH) is an interferon gamma–driven hyperinflammatory syndrome with high morbidity and mortality. Identifying reliable prognostic biomarkers is challenging due to various predisposing conditions and triggers. C-X-C-motif ligand 9 (CXCL9) is a clinically validated biomarker and surrogate marker of interferon gamma–mediated inflammation. We aimed to identify the role of CXCL9 in predicting severe disease and death in adults with HLH using a multicenter retrospective cohort of consecutively hospitalized patients who underwent a clinical evaluation for HLH that included CXCL9 testing. Patients were classified as HLH if they met HLH-2004 and/or HScore criteria. Conditional inference decision trees and Cox regression models were used to identify which clinical variables associated with acute mortality in patients with HLH. Overall, 171 patients were reviewed, and 126 patients met HLH criteria. The median age was 55 years (interquartile range, 40-66), with 62% male and 51% White. CXCL9 was markedly elevated in patients with HLH. Unbiased decision tree modeling, incorporating all clinical laboratory values, identified only CXCL9 of >16 100 pg/mL as the optimal predictor of inpatient mortality. Cox regression models demonstrated that CXCL9 of >16 100 pg/mL was significantly associated with 90-day mortality when controlling for important covariates. This shorter time to death in the elevated CXCL9 subgroup remained significant even after subdividing patients into those with malignancy (n = 53) and nonmalignancy HLH (n = 73). Continuous increases in CXCL9 within the cohort strongly associated with greater mortality. CXCL9 is a novel clinical marker that identifies high-risk HLH independent of underlying disease and could be used to select patients for early and aggressive targeted immunomodulatory therapy.
- Open Access
- 12 February 2026
- Published by American Society of Hematology in Blood
- Vol. 147 (7) , 755-767
Early time to relapse as a survival prognosticator in nodal mature T-cell lymphomas: results from the PETAL consortium
We assessed the overall survival (OS) impact of time to relapse (TTR) in multinational cohorts with independent observational and randomized validation. Patients with nMTCL with frontline complete response were assigned to TTR12 (≤12 months) or without TTR12 based on time to progression or next therapy. OS analyses included modified landmark (m-LM), standard landmark (s-LM), and time-dependent Cox (td-Cox), adjusting for age, histology, and prognostic index for T-cell lymphoma (PIT) score. Across 452 patients, 165 (36.5%) had TTR12, 181 (40%) relapsed at ≥12 months, and 106 (23.5%) remained relapse-free. TTR12 conferred worse OS using m-LM (hazard ratio [HR], 2.14; 95% confidence interval [CI], 1.58-2.90; P< .001), s-LM (HR, 1.92; 95% CI, 1.39-2.66; P< .001); and td-Cox (HR, 5.81; 95% CI, 2.94-11.46; P< .001). Results were consistent in the independent validation cohorts. TTR12 consistently conferred worse OS irrespective of frontline stem cell transplantation or PIT score, in peripheral T-cell lymphoma, not otherwise specified (m-LM: HR, 2.32; 95% CI, 1.51-3.55; P< .001; s-LM: HR, 2.10; 95% CI, 1.33-3.31; P = .001), anaplastic large cell lymphoma (m-LM: HR, 3.34; 95% CI, 1.18-9.50; P = .023; s-LM: HR, 2.96; 95% CI, 1.02-8.81; P = .046), and angioimmunoblastic T-cell/T follicular helper cell lymphoma (m-LM only: HR, 1.92; 95% CI, 1.15-3.21; P = .013). Second-line novel therapies improved OS (second-line start to death) vs chemotherapy in TTR12 only (HR, 0.60; 95% CI, 0.37-0.97; P = .038; without TTR12: HR, 0.82; 95% CI, 0.51-1.32; P = .407). TTR12 serves as a prognostic and potential OS surrogate marker, supporting stratification of new risk groups and need for their differential treatment.
- 12 February 2026
- Published by American Society of Hematology in Blood
- Vol. 147 (7) , 755-767
Open AccessEarly time to relapse as a survival prognosticator in nodal mature T-cell lymphomas: results from the PETAL consortium
We assessed the overall survival (OS) impact of time to relapse (TTR) in multinational cohorts with independent observational and randomized validation. Patients with nMTCL with frontline complete response were assigned to TTR12 (≤12 months) or without TTR12 based on time to progression or next therapy. OS analyses included modified landmark (m-LM), standard landmark (s-LM), and time-dependent Cox (td-Cox), adjusting for age, histology, and prognostic index for T-cell lymphoma (PIT) score. Across 452 patients, 165 (36.5%) had TTR12, 181 (40%) relapsed at ≥12 months, and 106 (23.5%) remained relapse-free. TTR12 conferred worse OS using m-LM (hazard ratio [HR], 2.14; 95% confidence interval [CI], 1.58-2.90; P< .001), s-LM (HR, 1.92; 95% CI, 1.39-2.66; P< .001); and td-Cox (HR, 5.81; 95% CI, 2.94-11.46; P< .001). Results were consistent in the independent validation cohorts. TTR12 consistently conferred worse OS irrespective of frontline stem cell transplantation or PIT score, in peripheral T-cell lymphoma, not otherwise specified (m-LM: HR, 2.32; 95% CI, 1.51-3.55; P< .001; s-LM: HR, 2.10; 95% CI, 1.33-3.31; P = .001), anaplastic large cell lymphoma (m-LM: HR, 3.34; 95% CI, 1.18-9.50; P = .023; s-LM: HR, 2.96; 95% CI, 1.02-8.81; P = .046), and angioimmunoblastic T-cell/T follicular helper cell lymphoma (m-LM only: HR, 1.92; 95% CI, 1.15-3.21; P = .013). Second-line novel therapies improved OS (second-line start to death) vs chemotherapy in TTR12 only (HR, 0.60; 95% CI, 0.37-0.97; P = .038; without TTR12: HR, 0.82; 95% CI, 0.51-1.32; P = .407). TTR12 serves as a prognostic and potential OS surrogate marker, supporting stratification of new risk groups and need for their differential treatment.
- 30 January 2026
- Published by Wiley in American Journal of Hematology
- Vol. 101 (6) , 1167-1172
CD19 CAR T‐Cell Therapy in Primary Cutaneous Diffuse Large B‐Cell Lymphoma, Leg Type
- 30 January 2026
- Published by Wiley in American Journal of Hematology
- Vol. 101 (6) , 1167-1172
CD19 CAR T‐Cell Therapy in Primary Cutaneous Diffuse Large B‐Cell Lymphoma, Leg Type